Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01357421 · ClinicalTrials.gov registry record · Phase 1
Effects of TT301 on Cytokine Levels Post Endotoxin Challenge
A Phase 1 study of Traumatic Brain Injury, sponsored by OPKO Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT01357421: Completed Phase 1 study of Traumatic Brain Injury, sponsored by OPKO Health.
NCT01357421 is a Phase 1 study of Traumatic Brain Injury that has completed, run by OPKO Health. The registered enrollment target is 18 participants, below the 277-participant average among 171 other Traumatic Brain Injury trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01357421, a Phase 1 study of Traumatic Brain Injury, has completed, sponsored by OPKO Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the effects of TT301 on cytokine levels in healthy male volunteers participating in an endotoxin challenge.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TT301
Study Locations (1)
North Carolina
- Duke Clinical Research Unit - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2011-05 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
What the finished NCT01357421 record still lists
NCT01357421 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 277-participant average among 171 other Traumatic Brain Injury trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Traumatic Brain Injury appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01357421 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT01357421 about?
NCT01357421 is a clinical study titled "Effects of TT301 on Cytokine Levels Post Endotoxin Challenge". This study will evaluate the effects of TT301 on cytokine levels in healthy male volunteers participating in an endotoxin challenge.
What is the current status of trial NCT01357421?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2011-05. Estimated completion is 2011-06.
What conditions does trial NCT01357421 study?
This clinical trial studies the following conditions: Traumatic Brain Injury.
What interventions are being tested in trial NCT01357421?
The interventions under investigation include: Placebo (DRUG), TT301 (DRUG).
Who is sponsoring clinical trial NCT01357421?
This trial is sponsored by OPKO Health, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01357421 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Traumatic Brain Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01357421's enrollment target sits among peer trials
18 153rd of 171 higher than 18 of 171 other Traumatic Brain Injury trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Traumatic Brain Injury trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Hyperpolarized 13C-pyruvate Metabolic MRI With Traumatic Brain Injury
RECRUITING · Phase 1
-
Safety and Efficacy of Angiotensin (1-7) in Persons With Moderate to Severe Traumatic Brain Injury
RECRUITING · Phase 1
-
Combinatory Rehabilitation Used for Substantially Helping Individuals With Traumatic Brain Injury
RECRUITING · Phase 1
-
Traumatic Brain Injury Peripheral Nerve Study
COMPLETED · Phase 1
-
Safety Study of RP-1127 (Glyburide for Injection) in Healthy Volunteers
COMPLETED · Phase 1
-
Functional Connectivity as a Biomarker of rTMS
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia